Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
D003606:Dacarbazine / Q000627:therapeutic use; D004341:Drug Evaluation; D004351:Drug Resistance; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011344:Procarbazine / Q000627:therapeutic use*; D012673:Semustine / Q000627:therapeutic use*
D009607:Nitrosourea Compounds; D012673:Semustine; D011344:Procarbazine; D003606:Dacarbazine